Vizsgálati helyszín
Azienda Unita Sanitaria Locale Della Romagna
Faenza, 48018, OlaszországMég nincs intézményhez kötve
- 16futó vizsgálat
- 10lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 26 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis16 vizsgálat
- 2. fázis8 vizsgálat
- 1/2. fázis2 vizsgálat
- Állapot
- Lezárult10 vizsgálat
- Fut, nem toboroz9 vizsgálat
- Toboroz6 vizsgálat
- Még nem toboroz1 vizsgálat
- Fő szponzor
- Anthos Therapeutics, Inc.3 vizsgálat
- F. Hoffmann-La Roche AG2 vizsgálat
- Fondazione IRCCS Istituto Nazionale Dei Tumori2 vizsgálat
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS2 vizsgálat
- Hoffmann-La Roche2 vizsgálat
- és még 15
Futó vizsgálatok
Toboroz
“A Phase II trial of atezolizumab plus CArboplatin plus nab-Paclitaxel as first-line Therapy in metastatic triple-negative PD-L1 positive breast cancer patients”
2024-519514-31-00· 2. fázis· Consorzio Oncotech· Forrás
Fut, nem toboroz
Study on the combination of two immunotherapeutic agents as pre-surgical therapy or definitive treatment in patients with resectable gastric or gastroesophageal junction cancer with microsatellite instability.
2024-518842-26-00· 2. fázis· Fondazione GONO G.I.· Forrás
Fut, nem toboroz
MITO 35a: a multicenter, prospective, single arm trial of Olaparib maintenance therapy in newly diagnosed BRCA wild-type advanced ovarian, fallopian tube and primitive peritoneal cancer
NCT05233982· 2. fázis· IRCCS Istituto Nazionale Tumori Fondazione Pascale· Forrás
Toboroz
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06497556· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
NCT05712200· 3. fázis· Anthos Therapeutics, Inc.· Forrás
Toboroz
Temozolomide and irinotecan consolidation in patients with MGMT silenced, microsatellite stable colorectal cancer with persistence of minimal residual disease in liquid biopsy after standard adjuvant chemotherapy: the ERASE-TMZ study
2024-515681-14-00· 2. fázis· Fondazione IRCCS Istituto Nazionale Dei Tumori· Forrás
Fut, nem toboroz
Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line
NCT05201547· 3. fázis· ARCAGY/ GINECO GROUP· Forrás
Fut, nem toboroz
Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients.
NCT04564898· 1/2. fázis· Gruppo Oncologico del Nord-Ovest· Forrás
Toboroz
MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.
NCT05255471· 3. fázis· National Cancer Institute, Naples· Forrás
Toboroz
Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer
NCT05136326· 2. fázis· Fondazione IRCCS Istituto Nazionale dei Tumori, Milano· Forrás
Fut, nem toboroz
MITO 25.1: A randomized, molecular driven phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib, selected according to HRD status, in patients with advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian tube cancer preceded by a phase I dose escalation study on Rucaparib-Bevacizumab combination.
2024-516632-99-00· 2. fázis· Fondazione Policlinico Universitario Agostino Gemelli IRCCS· Forrás
Toboroz
Phase 1b/2 trial of 5-fluorouracil, leucovorin, irinotecan in combination with temozolomide (FLIRT) and bevacizumab for the first-line treatment of patients with MGMT silenced, microsatellite stable metastatic colorectal cancer.
2024-515580-64-00· 1/2. fázis· Fondazione IRCCS Istituto Nazionale Dei Tumori· Forrás
Toboroz
Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study)
NCT04257487· 3. fázis· Arianna Anticoagulazione Foundation· Forrás
Fut, nem toboroz
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
NCT03937219· 3. fázis· Exelixis· Forrás
Fut, nem toboroz
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
NCT02319837· 3. fázis· Pfizer· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered in participants with PD-L1 ≥ 1% TC Stage IIB, IIIA, or select IIIB (T3N2 only) NSCLC following resection and adjuvant platinum-based chemotherapy
2023-506696-10-00· 3. fázis· F. Hoffmann-La Roche AG· Forrás
Fut, nem toboroz
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
NCT05609578· 2. fázis· Mirati Therapeutics Inc.· Forrás
Leállították
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
NCT05171075· 3. fázis· Anthos Therapeutics, Inc.· Forrás
Leállították
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
NCT05171049· 3. fázis· Anthos Therapeutics, Inc.· Forrás
Fut, nem toboroz
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
NCT05091567· 3. fázis· Hoffmann-La Roche· Forrás
Lezárult
Prospective, non randomized, Phase II study on MK-3475 in recurrent, platinum-resistant, CPS ≥1 positive ovarian, Fallopian tube and primary peritoneal cancer patients
2024-516629-30-00· 2. fázis· Fondazione Policlinico Universitario Agostino Gemelli IRCCS· Forrás
Lezárult
Phase 3 Study of Pembrolizumab and Lenvatinib in Combination with TACE for Incurable/Non-metastatic Hepatocellular Carcinoma
NCT04246177· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Lezárult
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung)
2023-505035-12-00· 3. fázis· F. Hoffmann-La Roche AG· Forrás
Lezárult
A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)
NCT03656536· 3. fázis· Incyte Corp.· Forrás
Fut, nem toboroz
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
NCT03602859· 3. fázis· Tesaro, Inc.· Forrás
Hibát jelzek